Marshall Wace
BTAI icon

Marshall Wace’s BioXcel Therapeutics BTAI Stock Holding History

Marshall Wace’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-1,763
Closed -$71.4K – 2199
2023
Q3 		$71.4K Buy
+1,763
New +$178K ﹤0.01% 2063
2022
Q3 		– Sell
-5,553
Closed -$1.17M – 3363
2022
Q2 		$1.17M Buy
+5,553
New +$1.17M ﹤0.01% 2350
2021
Q4 		– Sell
-781
Closed -$379K – 3878
2021
Q3 		$379K Buy
+781
New +$343K ﹤0.01% 2539

Other funds holding BTAI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BPA
Beacon Pointe Advisors Newport Beach, California $18.9B AUM 18.9% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Marshall Wace's BTAI Position: Q4 2023 in Review

Marshall Wace sold out of BioXcel Therapeutics (BTAI) in Q4 2023, closing a stake of 1,763 shares — an estimated $71.4K sold.

Marshall Wace first reported a position in BTAI in Q3 2021 and held it in 3 quarters. The position peaked at $1.17M in Q2 2022. 73 funds tracked by Wall St. Rank hold BTAI as of Q4 2023.

  • Marshall Wace reported no remaining BioXcel Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Marshall Wace sold 1,763 BioXcel Therapeutics shares in Q4 2023, an estimated $71.4K.
  • Marshall Wace first reported a position in BioXcel Therapeutics in Q3 2021 and held it in 3 quarters.
  • Marshall Wace's BioXcel Therapeutics position peaked at $1.17M in Q2 2022.
  • 73 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q4 2023.

Based on Marshall Wace's 13F filing for Q4 2023, filed 14 Feb 2024.